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Background-—Identifying pregnancy-associated risk factors before the development of major cardiovascular disease events could
provide opportunities for prevention. The objective of this study was to determine the association between outcomes in first
pregnancies and subsequent cardiovascular health.
Methods and Results-—The Nulliparous Pregnancy Outcomes Study Monitoring Mothers-to-be Heart Health Study is a prospective
observational cohort that followed 4484 women 2 to 7 years (mean 3.2 years) after their first pregnancy. Adverse pregnancy
outcomes (defined as hypertensive disorders of pregnancy, small-for-gestational-age birth, preterm birth, and stillbirth) were
identified prospectively in 1017 of the women (22.7%) during this pregnancy. The primary outcome was incident hypertension
(HTN). Women without adverse pregnancy outcomes served as controls. Risk ratios (RR) and 95% CIs were adjusted for age,
smoking, body mass index, insurance type, and race/ethnicity at enrollment during pregnancy. The overall incidence of HTN was
5.4% (95% CI 4.7% to 6.1%). Women with adverse pregnancy outcomes had higher adjusted risk of HTN at follow-up compared with
controls (RR 2.4, 95% CI 1.8-3.1). The association held for individual adverse pregnancy outcomes: any hypertensive disorders of
pregnancy (RR 2.7, 95% CI 2.0-3.6), preeclampsia (RR 2.8, 95% CI 2.0-4.0), and preterm birth (RR 2.7, 95% CI 1.9-3.8). Women who
had an indicated preterm birth and hypertensive disorders of pregnancy had the highest risk of HTN (RR 4.3, 95% CI 2.7-6.7).
Conclusions-—Several pregnancy complications in the first pregnancy are associated with development of HTN 2 to 7 years later.
Preventive care for women should include a detailed pregnancy history to aid in counseling about HTN risk.
Clinical Trial Registration-—URL: http://www.clinicaltrials.gov Unique identifier: NCT02231398. ( J Am Heart Assoc. 2019;8:
e013092. DOI: 10.1161/JAHA.119.013092.)
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C ardiovascular disease (CVD) is the leading cause ofmortality among women in the United States and
developed countries.1 Young women (<55 years old) in
particular are experiencing an increase in CVD risk factor
prevalence and severity, and CVD death rates have stagnated
in young women compared with other groups.2 In addition,
there is racial disparity in CVD: the US age-adjusted death
rate from coronary heart disease and stroke are markedly
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higher for non-Hispanic black than for non-Hispanic white
women.1 Dyslipidemia, inflammation, and central adiposity
are strongly related to CVD risk among women.3-5 Identifica-
tion of pathophysiology unique to women has considerable
potential to augment CVD prevention.6
Adverse pregnancy outcomes (APOs), such as hyperten-
sive disorders of pregnancy (HDP) and preterm birth (PTB),
were once regarded as obstetrical conditions with implica-
tions limited to pregnancy. However, mounting evidence
suggests that, after controlling for traditional risk factors for
these conditions, women who experience APOs are at
higher risk for subsequent development of hypertension
(HTN), CVD, and diabetes mellitus at younger ages than
those without APOs.7-10 Most studies have relied on
retrospectively collected data and/or self-reported repro-
ductive history11-16 and thus are prone to misclassification
or recall bias. Additionally, these studies have lacked
assessment of cardiometabolic status during the index
pregnancy, which also limits understanding of CVD risk
trajectory.
The nuMoM2b-HHS (Nulliparous Pregnancy Outcomes
Study—Monitoring Mothers-to-be Heart Health Study) was
designed to overcome these limitations. It had a primary
objective of establishing the association between pregnancy
outcomes and subsequent cardiovascular health by analyzing
data from a large cohort of women, with detailed clinical and
biospecimen data available, who were followed prospectively
from the beginning of their first pregnancy through 2 to
7 years postpartum.
Methods
The data that support the findings of this study are available
from the data-coordinating center on reasonable request.
Participants and Contact
The complete methods of the nuMoM2b-HHS are described
elsewhere.17 The study was approved by all local governing
institutional review boards. Briefly, contacts were made and
interviews performed by telephone or email at 6-month
intervals, beginning at least 6 months after delivery of the
index pregnancy. During interviews, women updated contact
information and answered questionnaires regarding any
subsequent pregnancies, medications, medical conditions,
and CVD events or diagnoses. Self-reported APOs or CVD
events subsequent to the index pregnancy were verified by
obtaining medical records. Details about interval contacts are
contained in the methods publication.17
Women were eligible to participate in an in-person cardiovas-
cular assessment if they participated in the nuMoM2b study18
(a prospective cohort of women in their first pregnancy recruited
in thefirst trimester), hadobstetrical delivery information fromthe
index pregnancy, agreed to be contacted for future studies, did
not subsequently withdraw consent during an interval contact,
and were 18 years of age or older, at least 2 years from the
delivery of their index pregnancy, and not currently pregnant. All
participants gave written informed consent approved by each
site’s human subjects ethical review board.
An in-person nuMoM2b-HHS visit was conducted 2 to
7 years after the index pregnancy ended. Participants were
asked to fast for 8 hours (including a long sleep period) before
the visit. Demographic characteristics, health care information,
current medication and supplement use, family and personal
medical history (including a detailed CVD medical history),
alcohol, tobacco, and drug use, and physical activity informa-
tion were obtained. Participants completed validated self-
administered questionnaires detailing food intake and eating
habits, sleep characteristics, perceived stress, depression, and
gynecologic health. In general, we used questions previously
demonstrated to be predictive of a clinical diagnosis and/or
standardized in large cohort studies.19,20 Blood pressure,
anthropometric measurements, and biological specimens were
collected at the visit using standardized protocols.
Measures, Outcomes, and Definitions
Pregnancy outcomes were recorded by study personnel at the
time of delivery and verified by trained, certified clinical chart
Clinical Perspective
What Is New?
• Hypertensive disorders of pregnancy and preterm birth
herald an increased risk of hypertension, particularly high
(45.4% by the new criteria) in women who had an iatrogenic
preterm birth, many of whom experienced hypertensive
disorders of pregnancy.
• When compared with women who developed other adverse
pregnancy outcomes, women with hypertensive disorders of
pregnancy, those diagnosed with preeclampsia, and women
with an iatrogenic preterm birth had a higher risk of
subsequent incident hypertension.
What Are the Clinical Implications?
• The short time frame (2-7 years) to the discovery of
hypertension after pregnancy among a population of young
women highlights the importance of a detailed pregnancy
history in preventive health screening, early diagnosis, and
intervention.
• First pregnancies might be utilized as an early life stress test
to identify women who may benefit from preventive and
screening strategies for healthy behaviors and therapies.
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abstractors. For participants with HTN, proteinuria, or a
related condition possibly consistent with HDP as noted in the
medical record, the chart review was more extensive in order
to classify HDP according to a priori study criteria or, in cases
when uncertainty as to the diagnosis remained, adjudication
by study investigators. HDP included all cases of preeclamp-
sia (without severe features, with severe features, superim-
posed preeclampsia, or eclampsia regardless of the timing of
onset) and antepartum gestational hypertension, with full
details of the categorization procedure described else-
where.21 Other APOs considered as exposures were PTB,
small-for-gestational-age birth, and stillbirth, defined per
standard obstetrical definitions.18 PTB was defined as a live
birth <37 weeks +0 days gestational age and based on prior
study definitions, further subclassified as iatrogenic (medically
indicated) PTB or spontaneous PTB. Small-for-gestational-age
birth was calculated using the Alexander growth curves from
birth weight and gestational age at birth and defined at less
than the 5th percentile.22 Gestational diabetes mellitus was
defined as failing standard glucose tolerance testing during
pregnancy without preexisting diabetes mellitus.23 Women
with only gestational diabetes mellitus are not included in the
current analysis of women with APOs. Analyses excluded
women who experienced pregnancy loss before 20 weeks or
pregnancy termination.
Blood pressure (BP) and anthropometric measures were
obtained during the nuMoM2b-HHS visit.17 Following a
standard protocol, research personnel recorded 3 standard-
ized BP measurements using calibrated automatic devices
that were the same at each site. With the participant seated,
BP measurements were recorded, and the average of the last
2 systolic and diastolic pressures were used for analysis.17
Body composition was assessed as body mass index
(kg/m²) from measures of height and weight obtained using a
regularly calibrated balance-beam scale for weight and a
stadiometer for height measurements. Waist circumference
over the iliac crest was measured to the nearest 0.1 cm using
a nonstretch study measuring tape. The measurement was
taken twice, and if the difference between the 2 was >0.5 cm,
a third measurement was recorded. For analyses, the third
measurement (if performed) or average of the first 2
measurements was used.
The primary outcome of the study was HTN that developed
subsequent to the index pregnancy, as determined by BP
measurement or use of an antihypertensive medication for
blood pressure control at the 2- to 7-year postpartum study
visit. HTN was chosen as the primary outcome due to its strong
association with CVD risk and death.24 The diagnostic
threshold for HTN was a systolic BP ≥140 mm Hg or a
diastolic BP ≥90 mm Hg.25,26 This diagnostic threshold,
determined as a study outcome based on the criteria for
HTN extant at the time the study was designed, was used for
the primary analyses. Unless specified, incident HTN is
diagnosed based on this definition. Recently updated guide-
lines, however, have redefined the lower threshold for HTN as a
systolic BP ≥130 mm Hg or a diastolic BP ≥80 mm Hg.24 We
performed a post hoc analysis using these thresholds as well.
Relevant cardiovascular health biomarkers were analyzed
using banked frozen maternal serum (lipid panel) and whole
blood (glucose) collected and processed at the nuMoM2b-
HHS study visit.17 Metabolic syndrome was defined as the
presence of 3 of the following 5 criteria: elevated waist
circumference, elevated triglycerides or taking medication to
lower them, elevated fasting glucose or taking associated
glucose-lowering medication, elevated blood pressure or
taking antihypertensive medication, reduced high-density
lipoprotein levels or taking associated medications.27
Statistical Considerations and Analysis
The sample size of5000 participants with nuMoM2b-HHS in-
person visits was determined a priori by considering detectable
HTN risk ratios and detectable mean differences in various
continuous measures of CVD risk at 2 to 7 years postpartum
for specific APOs versus comparison groups. Details are
described elsewhere.17 Briefly, assuming a 2% incidence of
HTN at follow-up for the non-APO controls, unadjusted risk
ratios from 2.1 to 2.7 for HTN amongwomenwith specific APOs
would be detectable with 80% power, assuming prevalence of
an individual APO ranging from 4% to 10%.
Index pregnancy characteristics and cardiovascular char-
acteristics at follow-up were summarized using means and
standard deviations for continuous variables, and frequency
and percentage for categorical variables. After exclusion of
women with chronic HTN before the index pregnancy or
missing HTN information at the study visit (Figure), univariate
associations between APOs and HTN were tested using chi-
squared tests for categorical variables and t tests for
continuous variables. The incidence of HTN 2 to 7 years after
the index pregnancy was estimated using binomial propor-
tions and Wald 95% CIs; exact Clopper-Pearson CIs were used
within small APO-specific subgroups (n≤40).
Poisson regression with robust standard errors28 was used
to estimate the risk ratios (RR) and 95% CIs of incident HTN
associated with any APOs. Unadjusted and adjusted (with the
covariates of age, body mass index, type of health insurance at
nuMoM2b enrollment, race/ethnicity, and smoking during the
3 months before pregnancy) associations were estimated. For
these analyses, associations between selected APOs and HTN
were tested using 3 comparison groups. Women with a specific
APO were compared with (1) women who did not have any of
the APOs in the index pregnancy, (2) women without the
specific APO (ie, any other APO or no APO), and (3) only women
with any other APO. These comparisons provide insight into
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relative contributions of each APO to the outcomes. We also
performed a sensitivity analysis restricted to women who did
not have a reported pregnancy between the end of the index
pregnancy and the nuMoM2b-HHS study visit.
We restricted these analyses to women who attended an
in-person visit in order to ensure the analyses were based on
objective measures of the primary outcome. Women with
missing data for the primary outcome, APOs, baseline HTN, or
model covariates were excluded from analyses involving those
data. Analyses were performed using SAS V9.4 (Cary, NC) and
R (Vienna, Austria).29,30
Results
After the exclusion criteria had been applied, 8838 of the
original 10 038 women enrolled in the nuMoM2b cohort were
eligible for nuMoM2b-HHS, and 7003 (79.2%) completed at
least 1 interval contact (Figure). Of these women, 4484
(64.0%) had an index pregnancy delivery at ≥20 weeks of
gestation and attended the in-person study visit. Table 1
displays the overall baseline characteristics of women who
attended a study visit. The demographic characteristics of the
nuMoM2b-HHS cohort were representative of the overall
nuMoM2b cohort18 and similar to women who did not
participate in nuMoM2b-HHS (Table S1). Rates of APOs in the
nuMoM2b-HHS cohort were also similar to the rates in the
overall nuMoM2b cohort (Table S1).
More than 1 in 5 women enrolled in nuMoM2b-HHS had at
least 1 APO during their index pregnancy (n=1017, 22.7%,
Table 1). HDP was the most common APO (13.6%; 6.6% with
preeclampsia and 7.0% with antepartum gestational HTN),
while 8.6% of women had a PTB (4.9% spontaneous PTB and
3.7% iatrogenic PTB), 4.2% had a small-for-gestational-age
birth, and 0.4% had a stillbirth. Many of the 167 cases of
Figure. Flow diagram for participation in analysis. APO indicates adverse pregnancy outcome;
HDP, hypertensive disorders of pregnancy; HHS, Heart Health Study; HTN, hypertension; iPTB,
indicated preterm birth; nuMoM2b, Nulliparous Pregnancy Outcome Study—Monitoring Mothers-
to-Be; PE, preeclampsia; PTB, preterm birth; sPTB, spontaneous preterm birth; SB, stillbirth; SGA,
small for gestational age.
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iatrogenic PTB had concomitant HDP (59.9%), and the
proportion was similar when only iatrogenic PTB <34 weeks
of gestation was considered (61.5%).
Index pregnancy characteristics of women in the study,
stratified by development of individual APOs, are displayed in
Table 1. When compared with women who did not have an
APO, women who developed an APO in the index pregnancy
were more likely to have been younger than 21 or older than
35 years of age, have a body mass index ≥25 kg/m2 at
index pregnancy enrollment, self-identified as non-Hispanic
black, had a lower level of education, had government or
military health insurance, and smoked during the 3 months
before the pregnancy (all P<0.05). These associations were
present for most individual APOs as well. Women who had
APOs were also more likely to have been diagnosed with
gestational diabetes mellitus during the pregnancy than
women who did not develop APOs (6.4% versus 3.7%
respectively, P<0.05).
Cardiovascular characteristics of the cohort 2 to 7 years
postpartum are shown in Table 2 (characteristics for all
subgroups in Table S2). The mean time between the end of
the index pregnancy and the study visit was 3.2 years (SD
0.9). A total of 1573 women (35.1%) did not have a pregnancy
in the intervening time before the study visit, 1931 (43.1%)
had 1 intervening pregnancy, and 980 (21.9%) had 2 or more;
54.5% were overweight or obese, an increase of 6.4% from
prepregnancy. Over one-third of all participants either had
high-density lipoprotein cholesterol <1.3 mmol/L (<50 mg/
dL) or were on a high-density lipoprotein–raising medication
(34.5%), whereas 12.0% had elevated triglycerides or were on
lipid-lowering medication. Twenty-two women (0.49%) had had
a verified cardiovascular event between the index pregnancy
and the study visit, 7 of which (31.8%) had occurred among
women who had had an APO in the index pregnancy (RR for
cardiovascular events for women with APOs compared with
women who did not have APOs 1.58, 95% CI 0.65-3.87;
Table S3).
The hypertensive status of all nuMoM2b-HHS participants
is provided in Table 3. HTN developed in 5.4% of women in
the cohort after their index delivery. Of the 235 women
meeting criteria for HTN, 196 (83.4%) were diagnosed by BP
measurements at the study visit, and 39 (16.6%) by currently
taking antihypertensive drugs. Utilizing the new diagnostic
thresholds for HTN published in 2018,24 we determined the
incidence of stage II HTN was 20.2%. Women who had been
diagnosed with APOs in their first pregnancy had higher mean
systolic and diastolic blood pressures (P<0.05) and higher
prevalence of HTN by all definitions (P<0.05). The incidence of
HTN in women with any APO was 10.8% but was 14.4% for
women who had had preeclampsia during their index preg-
nancy. Under the newer HTN definitions, these rates were
31.2% and 38.5%, respectively (Table 3). Women with anT
ab
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iatrogenic PTB in their index pregnancy had HTN incidence of
45.4% by the 2018 criteria.
The association of APOs (HDP, PTB, and stillbirth) in the
initial pregnancy remained associated with a greater likeli-
hood to develop HTN 2 to 7 years after pregnancy after
adjustment for covariates in multivariable regression (Table 4;
unadjusted analyses reported in Table S4). Table 4 presents
the RRs for APOs with HTN using 3 different reference groups:
comparison 1 compares women with APOs to women without
any APOs; comparison 2 compares women with APOs to
women without that specific APO; and comparison 3
compares women with APOs to women with other APOs.
Compared with women without any APOs in the index
pregnancy, women who had any APO had a higher risk of HTN
2 to 7 years later (RR 2.4, 95% CI 1.8-3.1). Specific APOs
(HDP, preeclampsia, and PTB; each compared with women
without APOs) were also significantly associated with a higher
incidence of subsequent HTN (Table 4, comparison 1).
Although the risk was high for women with PTB overall,
results suggest that women with an iatrogenic PTB had the
highest risk of subsequent HTN (RR 4.1, 95% CI 2.8-6.2).
When iatrogenic PTB cooccurred with HDP, there was also an
increased risk for subsequent HTN (RR 4.3, 95% CI 2.7-6.7).
When compared with women who developed other APOs,
women with HDP, those diagnosed with preeclampsia, and
women with an iatrogenic PTB had a higher risk of subsequent
incident hypertension (HDP: RR 1.6, 95% CI 1.0-2.4;
preeclampsia: RR 1.5, 95% CI 1.0-2.1; iatrogenic PTB: RR
2.0, 95% CI 1.4-3.0) (Table 4, comparison 3). These results
were mildly attenuated when the newer thresholds for the
diagnosis of HTN (>130/80) were used (Table S5).
To explore the degree to which the observed associations
were related to pregnancies occurring between the index
pregnancy and the nuMoM2b-HHS study visit, we performed a
sensitivity analysis limited to women who did not have any
pregnancies between these times. The adjusted RRs were
similar for women without intervening pregnancies and for
those in the overall cohort (data not shown).
Discussion
In this prospective study of women enrolled during their initial
pregnancy, women with at least 1 APO in their first pregnancy
had a significantly higher risk of HTN at the follow-up
assessment than women without APOs. For the cohort in
general, increased hypertension was apparent after only 2 to
7 years of follow-up. Our cohort also had high rates of
dyslipidemia at their study visits.
Although the prevalence of chronic HTN at the beginning of
the first pregnancy was 2.8% for women in this cohort, the
incidence of HTN only 2 to 7 years after the first pregnancy was
5.4%. The subgroup of womenwith aHDP had a 13.1% incidence
Table 2. Cardiovascular Characteristics 2 to 7 Years After
Index Pregnancy
Cardiovascular Characteristics 2
to 7 y After Index Pregnancy
All nuMoM2b-HHS
Participants
(N=4484)
BMI, kg/m2, mean (SD) 27.8 (7.7)
Category, n (%)
<25 kg/m2 2028 (45.5)
25 to <30 kg/m2 1081 (24.2)
≥30 kg/m2 1351 (30.3)
Waist circumference over iliac
crest, cm, mean (SD)
96.2 (16.5)
≥88 cm (non-Asian)
or ≥80 cm (Asian), n/N (%)
2916/4461 (65.4)
Total cholesterol,
mmol/L, mean (SD)
4.7 (1.0)
N with data 4403
HDL-C, mmol/L, mean (SD) 1.4 (0.3)
N with data 4403
<1.3 mmol/L or on
HDL-raising medication, n/N (%)
1517/4401 (34.5)
LDL-C, mmol/L, mean (SD) 2.8 (0.9)
N with data 4399
Glucose, mmol/L, mean (SD) 5.1 (1.3)
N with data 4395
≥5.6 mmol/L or on
glucose-lowering
medication, n/N (%)
718/4393 (16.3)
HbA1c, %, mean (SD) 5.3 (0.7)
N with data 4384
Insulin, pmol/L, mean (SD) 65.3 (89.0)
N with data 4381
Triglycerides, mmol/L,
mean (SD)
1.1 (0.7)
N with data 4404
≥1.7 mmol/L or on
lipid-lowering
medication, n/N (%)
530/4402 (12.0)
Creatinine, mmol/L, mean (SD) 13.1 (7.7)
N with data 4425
Albumin, mg/dL, mean (SD) 1.8 (6.7)
N with data 4425
Metabolic syndrome*, n/N (%) 732/4365 (16.8)
BMI indicates body mass index; HbA1c, glycated hemoglobin; HDL-C, high-density
lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; n, number in category;
N, sample size; nuMoM2b-HHS, Nulliparous Pregnancy Outcome Study—Monitoring
Mothers-to-Be—Heart Health Study.
*Metabolic syndrome is defined as the presence of 3 of 5 of the following criteria:
elevated waist circumference, elevated triglycerides or associated medication, elevated
fasting glucose or associated medication, elevated blood pressure or associated
medication, and reduced HDL-C or associated medication.
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of HTN. These frequencies are even higher (20.2% and 36.5%,
respectively) when the new guidelines for the diagnosis of HTN
are used.1 The short time frame to the development of
hypertension after pregnancy among a population of young
women highlights the potential importance of early diagnosis
and intervention. These data support the growing recognition
that first pregnanciesmight be utilized as an early life stress test
to identify women who may benefit from preventive and
screening strategies for healthy behaviors and therapies.7-9,31
Our findings build and expand on the findings of prior
research.32,33 A systematic review of studies that included
over 3 million women between 1960 and 2006 demonstrated
that women who had preeclampsia had a relative risk of
vascular disease of 3.7 after 14 years of mean follow-up, as
well as a relative risk of 2.2 and 1.8 for ischemic heart disease
and venous thromboembolism, respectively.10 More recently,
a study with a 4- to 12-year follow-up of 487 women
demonstrated that those with a PTB developed relatively
higher blood pressures and more atherogenic lipid profiles.34
In the Nurses’ Health Study II, women with self-recalled HDP in
their first pregnancy had higher rates of HTN, type 2 diabetes
mellitus, and hypercholesterolemia within 5 years after their
first birth.16 Higher mean BPs up to 20 years after pregnancy
were also seen in 916 women with prior PTB.12 Using
administrative records from deliveries in Florida, 1 report
noted that women with HDP had twice the risk of cardiovas-
cular readmissions within 3 years.35 Our results are consistent
in revealing that HDP and PTB herald an increased risk of HTN.
In contrast to other studies, our results are from prospectively
gathered and validated data for both the pregnancy as well as
the clinical outcomes. Because of this approach, we were able
not only to provide estimates of association less prone to bias
but also to identify additional granular associations, such as
the particularly high risk of HTN (45.4% by the new criteria) in
women who had an iatrogenic PTB—many of whom experi-
enced HDP. The higher risk for iatrogenic PTB than for
spontaneous PTB may be due to selection of a particularly
vulnerable subgroup for preterm delivery, whereas the condi-
tions surrounding spontaneous PTB are much more diverse.
We are unaware of other groups reporting substantially
increased rates of HTN for subgroups of women with particular
APOs this soon after a woman’s first delivery.
The interval between the index pregnancy and follow-up in
our study (mean of 3 years) was less than that in most other
cohorts, documenting how soon these risks may present. One
small case-control study (n=142) revealed an elevated risk of
hypertension at 2 years following delivery for women with
preeclampsia.36 The high rates of HTN in some of our
subgroups and the fact that 22 women already had a cardiac
event within our follow-up timeframe serve to underscore how
critical it is to identify women with increased risk in the early
postpartum time.
Bridging the disconnect between obstetric care and adult
preventive care is needed.37 As it is clear that women with
APOs are at increased risk of chronic diseases, more detailed
pregnancy histories may be important in preventive health
screening. The American Heart Association guidelines recom-
mend that providers take a careful and detailed history of
pregnancy complications that convey CVD risk and measure
BP at annual health screenings.6 Our findings support these
and similar recommendations from the American College of
Obstetricians and Gynecologists38,39 and further highlight the
importance of gathering detailed information about pregnancy
outcomes, given that APOs other than HDP are clearly, and to
different extents, associated with incident HTN.
The prospective nature of our large and socioeconomically
diverse cohort is a clear strength. We began following women
in the first trimester of their initial pregnancy, thus limiting
recall bias of items such as early pregnancy high body mass
index and health conditions developed during pregnancy. The
rigorous collection of information both from the index
pregnancy and afterwards is another strength.18 Carefully
ascertained and verified pregnancy outcomes and cardiovas-
cular outcomes at follow-up lend validity to the associations
identified in this study. Additionally, consistent objective
measurement of risk factors between the index pregnancy
and the nuMoM2b-HHS study visit, rather than self-report, is
another strength.
Our results are subject to limitations typical of observa-
tional cohort studies. We attempted to overcome several
potential biases by using a priori definitions, data collection
beginning in the first trimester of pregnancy, and robust
follow-up. It is possible that the women who responded to
interval contacts but did not attend an in-person visit would
have differed in their outcomes compared with women who
did return. Based on similar demographic characteristics
among women who did and did not have visits, this is less
likely (Table S1). It is also possible that behaviors and life
events, including subsequent pregnancies, during the inter-
vening years between the first pregnancy and the in-person
visit had a greater impact on the development of cardiovas-
cular risk than outcomes of the first pregnancy. However,
such associations do not negate the identified relationships
between the first pregnancy and subsequent development of
adverse outcomes. In fact, when the analysis was confined to
women with no intervening pregnancies, the relationship
between APOs and CVD risk persisted.
In conclusion, pregnancy complications during a woman’s
first pregnancy are associated with increased incidence of
HTN within 2 to 7 years, much earlier than previously
observed. Identification of high-risk APO combinations and
subtypes can guide postpartum counseling, health assess-
ments, and referrals to ensure appropriate monitoring for
cardiovascular risk factor development. Furthermore,
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engaging women who have had APOs to assess the efficacy of
lifestyle and other interventions to prevent CVD offers the
possibility of improving future cardiovascular health in a
focused and personalized manner.40
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Supplemental Table 1 
Index Pregnancy Characteristics of Original nuMoM2b Participants, nuMoM2b-HHS Participants Included in Analyses,  
and nuMoM2b and nuMoM2b-HHS Participants Not Included in Analyses 
Baseline Characteristics 
nuMoM2b 
Heart Health Study 
Included in Analyses 
Excluded from 
Analyses 
(N=10038) (N=4484) (N=5554) 
    
Maternal age, mean (SD), years 26.9 (5.7) 27.0 (5.6) 26.9 (5.7) 
  Category: n (%)       
      13-21 2133 (21.3%) 905 (20.2%) 1228 (22.2%) 
      22-35 7222 (72.0%) 3272 (73.0%) 3950 (71.2%) 
      >35 673 (6.7%) 307 (6.8%) 366 (6.6%) 
Maternal race: n (%)       
White Non-Hispanic 5989 (59.7%) 2786 (62.1%) 3203 (57.8%) 
Black Non-Hispanic 1418 (14.1%) 618 (13.8%) 800 (14.4%) 
Hispanic 1700 (17.0%) 735 (16.4%) 965 (17.4%) 
Asian 407 (4.1%) 135 (3.0%) 272 (4.9%) 
Other 514 (5.1%) 210 (4.7%) 304 (5.5%) 
Education level: n (%)       
Less than high school graduate 816 (8.1%) 327 (7.3%) 489 (8.8%) 
High school graduate or GED completed 1171 (11.7%) 508 (11.3%) 663 (12.0%) 
Some college credit, no degree 1948 (19.4%) 889 (19.8%) 1059 (19.1%) 
Associate/technical degree 1005 (10.0%) 501 (11.2%) 504 (9.1%) 
Bachelor's degree 2772 (27.7%) 1261 (28.1%) 1511 (27.3%) 
Degree beyond bachelor's 2308 (23.0%) 996 (22.2%) 1312 (23.7%) 
Type of health insurance: n (%)       
Commercial 6778 (68.1%) 3087 (69.2%) 3691 (67.1%) 
Government/military 2800 (28.1%) 1219 (27.3%) 1581 (28.7%) 
Self-pay/other 381 (3.8%) 152 (3.4%) 229 (4.2%) 
Smoked during 3 months prior to pregnancy: n / N (%) 1782/10018 (17.8%) 718/4478 (16.0%) 1064/5540 (19.2%) 
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Supplemental Table 1 (continued) 
Index Pregnancy Characteristics of Original nuMoM2b Participants, nuMoM2b-HHS Participants Included in Analyses,  
and nuMoM2b and nuMoM2b-HHS Participants Not Included in Analyses 
Baseline Characteristics 
nuMoM2b 
Heart Health Study 
Included in Analyses 
Excluded from 
Analyses 
(N=10038) (N=4484) (N=5554) 
    
Early Pregnancy BMI, mean (SD), kg/m2  26.3 (6.3) 26.6 (6.5) 26.0 (6.2) 
  Category: n (%)       
     <25 5247 (53.3%) 2284 (51.8%) 2963 (54.6%) 
     25 to <30 2437 (24.8%) 1081 (24.5%) 1356 (25.0%) 
     ≥30 2153 (21.9%) 1042 (23.6%) 1111 (20.5%) 
Pre-gestational hypertension: n / N (%) 243/9469 (2.6%) 127/4480 (2.8%) 116/4989 (2.3%) 
Pre-gestational diabetes: n / N (%) 151/9476 (1.6%) 62/4482 (1.4%) 89/4994 (1.8%) 
Gestational diabetes: n / N (%) 396/9415 (4.2%) 191/4422 (4.3%) 205/4993 (4.1%) 
Adverse Pregnancy Outcomes (APOs*): n / N (%)       
Hypertensive disorders of pregnancy 1244/9468 (13.1%) 612/4480 (13.7%) 632/4988 (12.7%) 
Preeclampsia 586/9468 (6.2%) 298/4480 (6.7%) 288/4988 (5.8%) 
Preterm birth 820/9473 (8.7%) 387/4480 (8.6%) 433/4993 (8.7%) 
Spontaneous preterm birth 477/9469 (5.0%) 218/4478 (4.9%) 259/4991 (5.2%) 
Indicated preterm birth 339/9469 (3.6%) 167/4478 (3.7%) 172/4991 (3.4%) 
Small for gestational age 424/9434 (4.5%) 187/4467 (4.2%) 237/4967 (4.8%) 
Stillbirth 51/9484 (0.5%) 16/4484 (0.4%) 35/5000 (0.7%) 
No APO: n / N (%) 7318/9414 (77.7%) 3444/4461 (77.2%) 3874/4953 (78.2%) 
Any APO: n / N (%) 2096/9414 (22.3%) 1017/4461 (22.8%) 1079/4953 (21.8%) 
Abbreviations:  BMI=body mass index; APO=adverse pregnancy outcome; n=number in category; N=sample size. 
* APO defined as: Hypertensive disorders of pregnancy, preterm birth, small for gestational age, or stillbirth. 
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Supplemental Table 2 
Cardiovascular Characteristics 2-7 Years After nuMoM2b Index Pregnancy, According to Index Pregnancy APOs*† 
Cardiovascular Characteristics 2-7 Years 
After nuMoM2b Index Pregnancy 
nuMoM2b Index Pregnancy APOs (not mutually exclusive) 
No APO Any APO HDP Preeclampsia PTB sPTB 
sPTB<34 
weeks iPTB SGA SB 
(N=3444) (N=1017) (N=612) (N=298) (N=387) (N=218) (N=57) (N=167) (N=187) (N=16) 
BMI, kg/m2, mean (SD) 27.3 (7.4) 29.9 (8.4)^ 31.2 (8.6)^ 31.6 (9.0)^ 29.4 (8.3)^ 27.6 (7.4) 29.9 (8.5)^ 31.6 (9.0)^ 27.8 (8.3) 30.8 (8.9) 
  Category: n (%)           
     <25 kg/m2  1681 (49.1%) 339 (33.5%)^ 165 (27.0%)^ 75 (25.3%)^ 133 (34.5%)^ 90 (41.5%) 16 (28.1%)^ 42 (25.3%)^ 88 (47.1%) 3 (20.0%) 
     25 to <30 kg/m2  813 (23.7%) 260 (25.7%)^ 160 (26.2%)^ 81 (27.3%)^ 102 (26.5%)^ 64 (29.5%) 18 (31.6%)^ 37 (22.3%)^ 43 (23.0%) 5 (33.3%) 
     ≥30 kg/m2  930 (27.2%) 414 (40.9%)^ 285 (46.7%)^ 141 (47.5%)^ 150 (39.0%)^ 63 (29.0%) 23 (40.4%)^ 87 (52.4%)^ 56 (29.9%) 7 (46.7%) 
Waist circumference over iliac crest, cm 
mean (SD) 
 
95.0 (15.8) 
 
100.4 (18.0)^ 
 
103.0 (18.5)^ 
 
103.6 (19.2)^ 
 
99.1 (17.9)^ 
 
96.0 (16.0) 
 
99.5 (15.8)^ 
 
103.4 (19.4)^ 
 
95.0 (16.6) 
 
102.5 (17.8) 
≥88 (non-Asian); ≥80 (Asian), n/N (%) 2161/3426 (63.1%) 743/1012 (73.4%)^ 474/608 (78.0%)^ 228/295 (77.3%)^ 270/384 (70.3%)^ 141/217 (65.0%) 46/57 (80.7%)^ 129/165 (78.2%)^ 115/187 (61.5%) 12/16 (75.0%) 
Total cholesterol, mmol/L, mean (SD) 4.7 (1.0) 4.8 (1.1)^ 4.8 (1.1)^ 4.8 (1.2)^ 4.7 (1.0) 4.7 (0.9) 4.7 (1.0) 4.8 (1.1) 4.6 (0.9) 5.0 (1.2) 
N with data 3385 997 603 294 379 216 56 161 182 14 
HDL-C, mmol/L, mean (SD) 1.5 (0.3) 1.4 (0.3)^ 1.4 (0.3)^ 1.3 (0.3)^ 1.4 (0.3)^ 1.4 (0.4)^ 1.3 (0.3)^ 1.3 (0.3)^ 1.4 (0.3)^ 1.4 (0.4) 
N with data 3385 997 603 294 379 216 56 161 182 14 
<1.3 or on HDL-raising med, n/N (%) 1101/3384 (32.5%) 410/996 (41.2%)^ 253/602 (42.0%)^ 136/294 (46.3%)^ 163/379 (43.0%)^ 80/216 (37.0%) 23/56 (41.1%) 81/161 (50.3%)^ 73/182 (40.1%)^ 7/14 (50.0%) 
LDL-C, mmol/L, mean (SD) 2.7 (0.9) 2.8 (0.9)^ 2.9 (1.0)^ 2.9 (1.0)^ 2.8 (0.8) 2.7 (0.8) 2.8 (0.8) 2.8 (1.0) 2.8 (0.8) 3.1 (1.0) 
N with data 3381 997 603 294 379 216 56 161 182 14 
Glucose, mmol/L, mean (SD) 5.0 (1.1) 5.3 (1.7)^ 5.3 (1.6)^ 5.4 (1.9)^ 5.5 (2.3)^ 5.4 (2.2)^ 5.6 (2.8) 5.7 (2.5)^ 5.0 (0.6) 6.1 (2.2) 
N with data 3380 994 602 294 379 216 56 161 180 14 
≥5.6 or on glucose-lowering med, n / N (%) 493/3379 (14.6%) 220/993 (22.2%)^ 140/601 (23.3%)^ 73/294 (24.8%)^ 98/379 (25.9%)^ 46/216 (21.3%)^ 15/56 (26.8%)^ 52/161 (32.3%)^ 26/180 (14.4%) 4/14 (28.6%) 
HbA1c, %, mean (SD) 5.2 (0.6) 5.4 (1.1)^ 5.4 (1.0)^ 5.5 (1.2)^ 5.6 (1.5)^ 5.5 (1.4)^ 5.6 (1.8) 5.7 (1.6)^ 5.2 (0.4) 6.1 (1.9) 
N with data 3372 991 596 290 380 217 57 161 180 14 
Insulin, pmol/L, mean (SD) 62.0 (88.0) 76.5 (91.8)^ 79.8 (96.2)^ 90.7 (120.1)^ 83.8 (111.8)^ 73.6 (95.9) 95.6 (129.8) 97.3 (129.6)^ 62.0 (60.2) 76.3 (52.6) 
N with data 3367 993 600 293 378 215 56 161 182 14 
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Supplemental Table 2 (continued) 
Cardiovascular Characteristics 2-7 Years After nuMoM2b Index Pregnancy, According to Index Pregnancy APOs* 
Cardiovascular Characteristics 2-7 Years 
After nuMoM2b Index Pregnancy 
nuMoM2b Index Pregnancy APOs (not mutually exclusive) 
No APO Any APO HDP Preeclampsia PTB sPTB 
sPTB<34 
weeks iPTB SGA SB 
(N=3444) (N=1017) (N=612) (N=298) (N=387) (N=218) (N=57) (N=167) (N=187) (N=16) 
           
Triglycerides, mmol/L, mean (SD) 1.0 (0.6) 1.2 (0.8)^ 1.2 (0.9)^ 1.3 (1.0)^ 1.3 (1.0)^ 1.1 (0.7)^ 1.4 (0.8)^ 1.4 (1.2)^ 1.0 (0.9) 1.2 (0.5) 
N with data 3386 997 603 294 379 216 56 161 182 14 
≥ 1.7 or on lipid-lowering med, n / N (%) 366/3385 (10.8%) 162/996 (16.3%)^ 111/602 (18.4%)^ 62/294 (21.1%)^ 70/379 (18.5%)^ 33/216 (15.3%)^ 12/56 (21.4%)^ 36/161 (22.4%)^ 16/182 (8.8%) 2/14 (14.3%) 
Creatinine, mmol/L, mean (SD) 12.9 (7.6) 13.7 (7.9)^ 13.7 (8.1)^ 14.9 (8.4)^ 14.0 (7.9)^ 13.7 (7.8) 14.9 (8.1) 14.4 (8.1)^ 14.1 (7.9)^ 14.1 (5.9) 
N with data 3404 999 602 294 382 216 55 164 184 14 
Albumin, mg/dL, mean (SD) 1.6 (5.3) 2.7 (9.8)^ 2.8 (10.2)^ 3.2 (11.3)^ 3.9 (14.4)^ 2.7 (10.6) 1.7 (3.4) 5.5 (18.2)^ 2.0 (4.8) 7.5 (22.8) 
N with data 3404 999 602 294 382 216 55 164 184 14 
Metabolic syndrome†, n / N (%) 476/3357 (14.2%) 254/987 (25.7%)^ 174/596 (29.2%)^ 92/291 (31.6%)^ 111/376 (29.5%)^ 46/215 (21.4%)^ 17/56 (30.4%)^ 65/159 (40.9%)^ 28/180 (15.6%) 4/14 (28.6%) 
Abbreviations: SD=standard deviation; n=number in category; N=sample size; BMI=body mass index; HDL-C=high density lipoprotein cholesterol; LDL-C=low density lipoprotein cholesterol; APO=adverse pregnancy outcome; GDM=gestational diabetes;  
   HDP=hypertensive disorders of pregnancy; PTB=preterm birth; sPTB=spontaneous preterm birth; iPTB=indicated preterm birth; SGA=small for gestational age; SB=stillbirth. Statistical significance for 'No APO' versus each of the other categories reported as: ^ = P<0.05. 
*APO defined as: Hypertensive disorders of pregnancy, preeclampsia, preterm birth, spontaneous preterm birth, indicated preterm birth, small for gestational age, or stillbirth. 
† Metabolic syndrome defined as: presence of three of five of the following criteria: elevated waist circumference, elevated triglycerides or associated medication, elevated fasting glucose or associated medication, elevated blood pressure or associated medication,  
   reduced HDL-C or associated medication. 
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Supplemental Table 3 
Major Cardiovascular Events Experienced  
Within 2-7 Years After Index Pregnancy 
Cardiovascular Event N (%) 
  
Congestive Heart Failure 5 (22.7%) 
Deep Venous Thrombosis 10 (45.5%) 
Peripheral Artery Disease 3 (13.6%) 
Pulmonary Embolism 8 (36.4%) 
Stroke 1 (4.5%) 
  
N=number with event. 22 women experienced a total  
   of 27 events. 
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Supplemental Table 4 
Association of nuMoM2b Index Pregnancy APOs* with Incident Hypertension 2-7 Years Later Among nuMoM2b-HHS Participants  
without Baseline Hypertension† (Covariate Unadjusted) 
    Hypertension 2-7 years after index delivery‡ 
APOs During Index Pregnancy n / N (%) (95% CI) 
n / N (%) 
(95% CI) ‖ 
RR (95% CI)  
Comparison 1# 
RR (95% CI) 
Comparison 2** 
RR (95% CI) 
Comparison 3€ 
         
Hypertensive disorders of pregnancy§ 581/4341 (13.4%) 
(12.4%, 14.4%) 
76/581 (13.1%) 
(10.3%, 15.8%) 
3.4 (2.6, 4.5) 3.1 (2.4, 4.0) 1.8 (1.2, 2.6) 
Preeclampsia 270/4341 (6.2%)  
(5.5%, 6.9%) 
39/270 (14.4%) 
(10.3%, 18.6%) 
3.8 (2.7, 5.3) 3.0 (2.2, 4.2) 1.6 (1.1, 2.3) 
Preterm birth 357/4337 (8.2%)  
(7.4%, 9.0%) 
43/357 (12.0%) 
(8.7%, 15.4%) 
3.2 (2.3, 4.4) 2.5 (1.8, 3.4) 1.2 (0.8, 1.7) 
Spontaneous preterm birth 214/4335 (4.9%)  
(4.3%, 5.6%) 
14/214 (6.5%) 
(3.2%, 9.9%) 
1.7 (1.0, 2.9)^ 1.2 (0.7, 2.1) 0.5 (0.3, 0.9) 
Indicated preterm birth 141/4335 (3.3%)  
(2.7%, 3.8%) 
29/141 (20.6%) 
(13.9%, 27.2%) 
5.4 (3.7, 7.8) 4.2 (3.0, 6.0) 2.2 (1.5, 3.3) 
Small for gestational age 178/4324 (4.1%)  
(3.5%, 4.7%) 
9/178 (5.1%) 
(1.8%, 8.3%) 
1.3 (0.7, 2.6) 0.9 (0.5, 1.8) 0.4 (0.2, 0.8) 
Stillbirth 15/4341 (0.3%)  
(0.2%, 0.5%) 
3/15 (20.0%) 
(4.3%, 48.1%) 
5.2 (1.9, 14.6) 3.7 (1.3, 10.3) 1.9 (0.7, 5.2) 
Any APO 967/4322 (22.4%)  
(21.1%, 23.6%) 
104/967 (10.8%) 
(8.8%, 12.7%) 
2.8 (2.2, 3.6) N/A N/A 
No APO 3355/4322 (77.6%)  
(76.4%, 78.9%) 
128/3355 (3.8%) 
(3.2%, 4.5%) 
N/A N/A N/A 
Abbreviations:  APO=adverse pregnancy outcome; RR=risk ratio; CI=confidence interval; n=number in category; N=sample size; 
* APO defined as: Hypertensive disorders of pregnancy, preterm birth, small for gestational age, or stillbirth. 
† Baseline Hypertension defined as: prior diagnosis of hypertension per nuMoM2b chart abstraction. 
‡ Hypertension 2-7 years after index pregnancy defined as: HHS measured 140≤SBP/90≤DBP or self-report of antihypertensive medication use. 
§ Hypertensive disorders of pregnancy include all cases of preeclampsia (mild, severe, or superimposed preeclampsia or eclampsia regardless of the timing of onset) and antepartum gestational  
  hypertension 
‖ For denominators ≤40, exact (Clopper-Pearson) confidence intervals are computed. Otherwise, Wald confidence intervals are computed. 
# Risk ratio for the comparison of specific APO vs. no APOs. 
** Risk ratio for the comparison of specific APO vs. absence of the specific APO. 
€ Risk ratio for the comparison of specific APO vs. other APOs. The ^ designates instances where the confidence interval includes 1.0 but a boundary value is reported as 1.0 due to rounding.  
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Supplemental Table 5 
Association of nuMoM2b Index Pregnancy APOs* with Incident Hypertension (AMA 2018) 2-7 Years Later Among nuMoM2b-HHS Participants  
without Baseline Hypertension† (Covariate Adjusted) 
    Hypertension 2-7 years after index delivery‡ 
APOs During Index Pregnancy n / N (%) 
(95% CI) 
n / N (%) 
(95% CI) ‖ 
RR (95% CI)  
Comparison 1# 
RR (95% CI) 
Comparison 2** 
RR (95% CI) 
Comparison 3€ 
      
Hypertensive disorders of pregnancy§ 581/4341 (13.4%)  
(12.4%, 14.4%) 
212/581 (36.5%)  
(32.6%, 40.4%) 
1.7 (1.5, 2.0) 1.7 (1.5, 2.0) 1.5 (1.2, 1.9) 
Preeclampsia 270/4341 (6.2%)  
(5.5%, 6.9%) 
104/270 (38.5%)  
(32.7%, 44.3%) 
1.8 (1.5, 2.2) 1.7 (1.4, 2.0) 1.3 (1.1, 1.6) 
Preterm birth 357/4337 (8.2%)  
(7.4%, 9.0%) 
105/357 (29.4%)  
(24.7%, 34.1%) 
1.5 (1.3, 1.8) 1.4 (1.2, 1.7) 1.0 (0.8, 1.2) 
Spontaneous preterm birth 214/4335 (4.9%)  
(4.3%, 5.6%) 
41/214 (19.2%)  
(13.9%, 24.4%) 
1.0 (0.8, 1.4) 0.9 (0.7, 1.2) 0.6 (0.4, 0.8) 
Indicated preterm birth 141/4335 (3.3%)  
(2.7%, 3.8%) 
64/141 (45.4%)  
(37.2%, 53.6%) 
2.2 (1.8, 2.6) 2.0 (1.6, 2.4) 1.6 (1.3, 1.9) 
Small for gestational age 178/4324 (4.1%)  
(3.5%, 4.7%) 
41/178 (23.0%)  
(16.8%, 29.2%) 
1.3 (1.0, 1.7) 1.1 (0.9, 1.5) 0.7 (0.5, 1.0) 
Stillbirth 15/4341 (0.3%)  
(0.2%, 0.5%) 
6/15 (40.0%)  
(16.3%, 67.7%) 
1.8 (1.0, 3.4) 1.6 (0.9, 3.0) 1.2 (0.7, 2.1) 
Any APO 967/4322 (22.4%)  
(21.1%, 23.6%) 
302/967 (31.2%)  
(28.3%, 34.2%) 
1.6 (1.4, 1.8) N/A N/A 
No APO 3355/4322 (77.6%)  
(76.4%, 78.9%) 
571/3355 (17.0%)  
(15.7%, 18.3%) 
N/A N/A N/A 
Abbreviations:  APO=adverse pregnancy outcome; AMA 2018=hypertension guidelines from American College of Cardiology and American Medical Association 2018; RR=risk ratio;  
    CI=confidence interval; n=number in category; N=sample size. 
* APO defined as: Hypertensive disorders of pregnancy, preterm birth, small for gestational age, or stillbirth. 
† Baseline Hypertension defined as: prior diagnosis of hypertension per nuMoM2b chart abstraction. 
‡ Hypertension 2-7 years after index pregnancy defined as: HHS measured 140≤SBP/90≤DBP or self-report of antihypertensive medication use. 
§ Hypertensive disorders of pregnancy include all cases of preeclampsia (mild, severe, or superimposed preeclampsia or eclampsia regardless of the timing of onset) and antepartum gestational  
  hypertension 
‖ For denominators ≤40, exact (Clopper-Pearson) confidence intervals are computed. Otherwise, Wald confidence intervals are computed. 
# Risk ratio for the comparison of specific APO vs. no APOs. 
** Risk ratio for the comparison of specific APO vs. absence of the specific APO. 
€ Risk ratio for the comparison of specific APO vs. other APOs. The ^ designates instances where the confidence interval includes 1.0 but a boundary value is reported as 1.0 due to rounding.  
 
